UB Paderborn / Katalog / Suche / in CDI

Elevated serum homocysteine is a predictor of accelerated decline in renal function and chronic kidney disease: A historical prospective study

European journal of internal medicine, 2014-12, Vol.25 (10), p.951-955

2014

Link zum Volltext

Verfügbarkeit prüfen

A minimal PBPK model to accelerate preclinical development of drugs against tuberculosis

Frontiers in pharmacology, 2024-01, Vol.14, p.1272091-1272091

2024

Link zum Volltext

Verfügbarkeit prüfen

Analysis of hepatitis C virus decline during treatment with the protease inhibitor danoprevir using a multiscale model

PLoS computational biology, 2013-03, Vol.9 (3), p.e1002959-e1002959

2013

Link zum Volltext

Verfügbarkeit prüfen

Pharmacokinetics, metabolism and safety of deuterated L‐DOPA (SD‐1077)/carbidopa compared to L‐DOPA/carbidopa following single oral dose administration in healthy subjects

British journal of clinical pharmacology, 2018-10, Vol.84 (10), p.2422-2432

2018

Link zum Volltext

Verfügbarkeit prüfen

Exposure-response relationship of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in a large population of patients with rheumatoid arthritis

Journal of clinical pharmacology, 2013-02, Vol.53 (2), p.151-159

2013

Link zum Volltext

Verfügbarkeit prüfen

Population pharmacokinetics of daptomycin in adult patients undergoing continuous renal replacement therapy

British journal of clinical pharmacology, 2017-03, Vol.83 (3), p.498-509

2017

Link zum Volltext

Verfügbarkeit prüfen

Population pharmacokinetic modelling and simulation of fremanezumab in healthy subjects and patients with migraine

British journal of clinical pharmacology, 2019-12, Vol.85 (12), p.2721-2733

2019

Link zum Volltext

Verfügbarkeit prüfen

Effect of Fremanezumab Monthly and Quarterly Doses on Efficacy Responses

Headache, 2020-07, Vol.60 (7), p.1376-1391

2020

Link zum Volltext

Verfügbarkeit prüfen

383. Pharmacokinetics and Safety in Healthy Adults of RSM01, a Novel RSV Monoclonal Antibody, and Population PK Modeling to Support Pediatric Development

Open forum infectious diseases, 2023-11, Vol.10 (Supplement_2)

2023

Link zum Volltext

Verfügbarkeit prüfen

Population Pharmacokinetic and Pharmacokinetic/Pharmacodynamic Modeling of Weight‐Based Intravenous Reslizumab Dosing

Journal of clinical pharmacology, 2020-08, Vol.60 (8), p.1039-1050

2020

Link zum Volltext

Verfügbarkeit prüfen

Exposure-Exposure Relationship of Tocilizumab, an Anti-IL-6 Receptor Monoclonal Antibody, in a Large Population of Patients With Rheumatoid Arthritis

Journal of clinical pharmacology, 2013-02, Vol.53 (2), p.151-159

2013

Link zum Volltext

Verfügbarkeit prüfen

Selective radioprotection of hepatocytes by systemic and portal vein infusions of amifostine in a rat liver tumor model

International journal of radiation oncology, biology, physics, 2001-06, Vol.50 (2), p.473-478

2001

Link zum Volltext

Verfügbarkeit prüfen

127 Cardiovascular Safety Assessment of Deutetrabenazine in Healthy Volunteers and Implications for Patients With Huntington Disease or Tardive Dyskinesia

CNS spectrums, 2018-02, Vol.23 (1), p.80-80

2018

Link zum Volltext

Verfügbarkeit prüfen

Modeling viral kinetics and treatment outcome during alisporivir interferon‐free treatment in hepatitis C virus genotype 2 and 3 patients

Hepatology (Baltimore, Md.), 2014-05, Vol.59 (5), p.1706-1714

2014

Link zum Volltext

Verfügbarkeit prüfen

Population Pharmacokinetic Modeling and Simulation of TV‐46000: A Long‐Acting Injectable Formulation of Risperidone

Clinical pharmacology in drug development, 2022-07, Vol.11 (7), p.865-877

2022

Link zum Volltext

Verfügbarkeit prüfen

A pharmacokinetic – viral kinetic model describes the effect of alisporivir monotherapy or in combination with peg-IFN on 2 hepatitis C virologic response

Clinical pharmacology and therapeutics, 2014-11, Vol.96 (5), p.599-608

2014

Link zum Volltext

Verfügbarkeit prüfen

Modeling viral kinetics and treatment outcome during alisporivir interferon-free treatment in hepatitis C virus genotype 2 and 3 patients: HEPATOLOGY, Vol. XX, NO. X, 2014 GUEDJ ET AL

Hepatology (Baltimore, Md.), 2014-05, Vol.59 (5), p.1706-1714

2014

Link zum Volltext

Verfügbarkeit prüfen

Regional pharmacokinetics of amifostine in anesthetized dogs: role of the liver, gastrointestinal tract, lungs, and kidneys

Drug metabolism and disposition, 2002-12, Vol.30 (12), p.1425

2002

Link zum Volltext

Verfügbarkeit prüfen

Analysis of Hepatitis C Virus Decline during Treatment with the Protease Inhibitor Danoprevir Using a Multiscale Model: e1002959

PLoS computational biology, 2013-03, Vol.9 (3)

2013

Link zum Volltext

Verfügbarkeit prüfen

Exposure-Exposure Relationship of Tocilizumab, an Anti-IL-6 Receptor Monoclonal Antibody, in a Large Population of Patients With Rheumatoid Arthritis

Journal of clinical pharmacology, 2013-01

2013

Link zum Volltext

Verfügbarkeit prüfen

Prediction methods for nicotine clearance using cotinine and 3-hydroxy-cotinine spot saliva samples II. Model application

Journal of pharmacokinetics and pharmacodynamics, 2007-02, Vol.34 (1), p.23-34

2007

Link zum Volltext

Verfügbarkeit prüfen

Rituximab Exhibits a Long Half-Life Based on a Population Pharmacokinetic Analysis in Non-Hodgkin's Lymphoma (NHL) Patients

Blood, 2007-11, Vol.110 (11), p.2371-2371

2007

Link zum Volltext

Verfügbarkeit prüfen

Population pharmacokinetics of nicotine and its metabolites I. Model development

Journal of pharmacokinetics and pharmacodynamics, 2007-02, Vol.34 (1), p.5-21

2007

Link zum Volltext

Verfügbarkeit prüfen

Pharmacokinetics and antiepileptic activity of valproyl hydroxamic acid derivatives

Pharmaceutical research, 1997-02, Vol.14 (2), p.213-217

1997

Link zum Volltext

Verfügbarkeit prüfen

Menü

Weitere Dienste

Einstellungen

Elevated serum homocysteine is a predictor of accelerated decline in renal function and chronic kidney disease: A historical prospective study

A minimal PBPK model to accelerate preclinical development of drugs against tuberculosis

Analysis of hepatitis C virus decline during treatment with the protease inhibitor danoprevir using a multiscale model

Pharmacokinetics, metabolism and safety of deuterated L‐DOPA (SD‐1077)/carbidopa compared to L‐DOPA/carbidopa following single oral dose administration in healthy subjects

Exposure-response relationship of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in a large population of patients with rheumatoid arthritis

Population pharmacokinetics of daptomycin in adult patients undergoing continuous renal replacement therapy

Population pharmacokinetic modelling and simulation of fremanezumab in healthy subjects and patients with migraine

Effect of Fremanezumab Monthly and Quarterly Doses on Efficacy Responses

Dose selection for fremanezumab (AJOVY) phase 3 pediatric migraine studies using pharmacokinetic data from a pediatric phase 1 study and a population pharmacokinetic modeling and simulation approach

383. Pharmacokinetics and Safety in Healthy Adults of RSM01, a Novel RSV Monoclonal Antibody, and Population PK Modeling to Support Pediatric Development

Population Pharmacokinetic and Pharmacokinetic/Pharmacodynamic Modeling of Weight‐Based Intravenous Reslizumab Dosing

Exposure-Exposure Relationship of Tocilizumab, an Anti-IL-6 Receptor Monoclonal Antibody, in a Large Population of Patients With Rheumatoid Arthritis

Selective radioprotection of hepatocytes by systemic and portal vein infusions of amifostine in a rat liver tumor model

127 Cardiovascular Safety Assessment of Deutetrabenazine in Healthy Volunteers and Implications for Patients With Huntington Disease or Tardive Dyskinesia

Modeling viral kinetics and treatment outcome during alisporivir interferon‐free treatment in hepatitis C virus genotype 2 and 3 patients

Population Pharmacokinetic Modeling and Simulation of TV‐46000: A Long‐Acting Injectable Formulation of Risperidone

A pharmacokinetic – viral kinetic model describes the effect of alisporivir monotherapy or in combination with peg-IFN on 2 hepatitis C virologic response

Modeling viral kinetics and treatment outcome during alisporivir interferon-free treatment in hepatitis C virus genotype 2 and 3 patients: HEPATOLOGY, Vol. XX, NO. X, 2014 GUEDJ ET AL

Regional pharmacokinetics of amifostine in anesthetized dogs: role of the liver, gastrointestinal tract, lungs, and kidneys

Analysis of Hepatitis C Virus Decline during Treatment with the Protease Inhibitor Danoprevir Using a Multiscale Model: e1002959

Exposure-Exposure Relationship of Tocilizumab, an Anti-IL-6 Receptor Monoclonal Antibody, in a Large Population of Patients With Rheumatoid Arthritis

Prediction methods for nicotine clearance using cotinine and 3-hydroxy-cotinine spot saliva samples II. Model application

Rituximab Exhibits a Long Half-Life Based on a Population Pharmacokinetic Analysis in Non-Hodgkin's Lymphoma (NHL) Patients

Population pharmacokinetics of nicotine and its metabolites I. Model development

Pharmacokinetics and antiepileptic activity of valproyl hydroxamic acid derivatives

Suchergebnisse filtern